| Literature DB >> 36061386 |
Rebecca Alison Fabricius1, Camilla Birgitte Sørensen1, Liselotte Skov1, Nanette Mol Debes1,2.
Abstract
Cytokines are an important modulator of the immune system and have been found to be altered significantly in many neurological and psychiatric disorders, like obsessive compulsive disorder (OCD) and movement disorders. Also, in pediatric autoimmune neuropsychiatric disorders associated with group A streptococcal infections (PANDAS), which are characterized by abrupt debut of symptoms of OCD and /or movement disorder symptoms, alterations in the immune system have been suggested. The aim of this paper was to review the current literature on the cytokine profile of pediatric patients with symptoms of OCD and/or movement disorder symptoms. A search of PubMed and Medline was performed with specific keywords to review studies measuring cytokines in pediatric patients with symptoms of OCD and/or movement disorders. Nineteen studies were found, twelve of which included a healthy control group, while four studies had control groups of children with other disorders, primarily neurological or psychiatric. One study compared cytokines measurements to reference intervals, and two studies had a longitudinal design. Many cytokines were found to have significant changes in patients with symptoms of OCD and/or movement disorders compared to both healthy controls and other control groups. Furthermore, differences were found when comparing cytokines in periods of exacerbation with periods of remission of symptoms in study participants. The cytokines that most studies with healthy control groups found to be significantly altered were TNF-α, IL-1β and IL-17. Although the exact role of these cytokines in OCD and movement disorder symptoms remains unclear, the available literature suggests a proinflammatory cytokine profile. This offers interesting perspectives on the pathogenesis of OCD and/or movement disorder symptoms in children, and further research into the implications of cytokines in neuropsychiatric disorders is warranted.Entities:
Keywords: autoimmune; cytokines; movement disorders; obsessive-compulsive; pro-inflammatory
Year: 2022 PMID: 36061386 PMCID: PMC9437446 DOI: 10.3389/fped.2022.893815
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.569
Studies examining cytokines in pediatric patients with obsessive-compulsive and/or tic symptoms compared to healthy controls.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Bos-Veneman et al. ( | TS or CTD | 66 (71) | 56% of patients used psychotropic medication, antipsychotic primarily | Serum | Cytokines measured with multiplex cytokine array, read on luminex platform | IL-2, IL-4, IL-5, IL-12, sIL-2R, TNF-α, IFN-γ, sVCAM-1 and sICAM-1 | No differences found, but lower frequency of detectable IFN-g levels in patients, medication had no association with levels of cytokines |
| Cheng et al. ( | TS | 40 (40) | Unknown how many patients received any medication | Plasma | Cytokines measured using solid phase sandwich ELISA | IL-6, sIL-6R, IL-1β, sgp130 and IL-17 | IL-1β, IL-6, IL-17 and sgp130 were increased, and sIL-6R was decreased. Also found higher proportion IL-6 positive lymphocytes and IL-17 positive lymphocytes |
| Çolak Sivri et al. ( | OCD, no coexisting tics | 44 (40) | Patients were psychiatric medication naive, apart from 5 who had a history of medication but were unmedicated at time of study | Serum | Cytokines and chemokines measured using ELISA | IL-12, IL-17, TGF-β, TNF-α, sTNFR1, sTNFR2, IL-1β, CCL3, CCL,24, CXCL8, BDNF | TNF-α higher for OCD, while IL-12 lower |
| Gabbay et al. ( | TS (+/- OCD) | 32 (16) | 22% patients were medication naive, 78% were taking psychotropic medication at assessment | Plasma | Cytokines measured using ELISA, except for TNF-α, IL-1β, IL-12, IL-6 and IL-2 here specific high sensitivity human quantikine assays were used | TNF-α, IL-12, IL-β, IL-6 and IL-2 | TS+OCD subgroup elevated IL-12 compared to control and IL-2 increased in TS+OCD compared to TS-OCD. No changes when adjusted for psychotropic medication |
| Gariup et al. ( | OCD and tics | 8 in OCD and tics group (34) | All patients received some form of medication | Serum | Cytokines measured with Luminex ultra-sensitive kit, except IP-10 and MCP-1 were measured with ELISA | IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL 10, GM-CSF, IFN-γ, TNF-α, IFN-γ-IP-10, MCP-1 | IL-1β and IL-8, IP-10 higher for OCD and tics |
| Leckman et al. ( | OCD (+/- PANDAS) | 46 (31) | Majority of patients were receiving medication to control tics and/or OCD symptoms | Serum | Cytokines measured at study entry and exacerbations with multiplex ELISA | IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, INF-α, INF-γ, TNF-α | TNF-α and IL-12 levels higher in patients, non-PANDAS more likely than PANDAS to have elevated TNF-α. Patients not receiving medication had highest baseline level of IL-12 and TNF-α. IL-5 was higher for non-medicated than medicated and |
| Li et al. ( | TS | 58 (30) | Treatment experience including dopaminergic receptor antagonists was exclusion criteria | Serum | ytokines measured with ELISA | IL-6, IL-8, and TNF-α | Decrease in levels of both IL-6 and IL-8 and increase in the level of TNF-α |
| Matz et al. ( | TS | 46 (43) | 65 % of patients received psychotropic medication | Serum | Cytokines measured with Bio-Plex cytokine assay, except for IL1-ra and CD14 a specific quantikine Immunoassay was used for each | TNF-α, IL-6, CD14 and IL1-ra | TNF-α, IL1-ra and CD14 lower for TS children (unclear how many had comorbid OCD). No differences between medicated and non-medicated patients. |
| Pranzatelli et al. ( | TS with streptococcus markers | 5 (26) | Patients were one week off medication when examined, all were medicated | Serum and CSF | Cytokines measured with ELISA | Intracellular IFN-γ and IL-4, CXCL13, CXCL10, CCL19, CCL21 and CCL22 | No differences found. |
| Rodriguez et al. ( | OCD | 102 (47) | 80% of patients were medicated | Monocytes | LPS stimulated cytokines measured with multiplex luminex assay | IL-1β, IL-6, GM-CSF, TNF-α and IL-8 | Higher production of IL-1β, IL-6, GM-CSF, TNF-α and IL-8. Levels were higher for unmedicated patients than medicated, which were higher than controls |
| Simşek et al. ( | OCD | 34 (34) | Psychotropics were exclusion criteria, unclear if all were medication naive | Serum | Cytokines were measured with BD cytometric Bead Array analysis | IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ and TNF-α | Patients had increase in IL-2, TNF-α and IL-17A |
| Yeon et al. ( | TS | 26 | 62% of patients were unmedicated | Serum | Cytokines were measured using ELISA | MCP-1, IL-1β, IL-17A, IL-6, IL-12p70, and TNF-α | IL-17A, IL-12p70, IL-6 and TNF-α were increased in patients. TNFα was found to increase in unmedicated patients compared to patients taking medication |
BDNF, brain derived neurotrophic factor; CCL, CC motif chemokine ligand; CD, cluster of differentiation; CSF, cerebrospinal fluid; CTD, chronic tic disorder; CXCL, C-X-C motif chemokine ligand; ELISA, enzyme linked immunosorbent assay; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; IL1-ra, IL-1 receptor antagonist; IP, interferon gamma-induced protein; LPS, lipopolysaccharide; MCP, membrane cofactor protein; OCD, obsessive-compulsive disorder; PANDAS, pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections; sgp, soluble glycoprotein; sI/VCAM, soluble intercellular/vascular cell adhesion molecule; sTNFR, soluble TNF receptor; TNF, tumor necrosis factor; TS, Tourette syndrome.
Overview of cytokine changes in studies in pediatric patients with tics and/or obsessive-compulsive symptoms compared to healthy controls.
|
|
|
|
|
|---|---|---|---|
| TNF-α | Çolak Sivri et al. ( | Matz et al. ( | Bos-Veneman et al. ( |
| IL-6 | Rodriguez et al. ( | Li et al. ( | Leckman et al. ( |
| IL-1β | Gariup et al. ( | Çolak Sivri et al. ( | |
| IL-2 | Gabbay et al. ( | Bos-Veneman et al. ( | |
| IL-17(A) | Cheng et al. ( | Çolak Sivri et al. ( | |
| IL-12 | Gabbay et al. ( | Çolak Sivri et al. ( | Bos-Veneman et al. ( |
| IL-8 | Gariup et al. ( | Li et al. ( | |
| GM-CSF | Rodriguez et al. ( | Gariup et al. ( | |
| IP-10 | Gariup et al. ( | ||
| IL-12p70 | Yeon et al. ( | ||
| IL1-ra | Matz et al. ( | ||
| CD-14 | Matz et al. ( | ||
| sgp130 | Cheng et al. ( | ||
| sIL-6R | Cheng et al. ( |
CD, cluster of differentiation; GM-CSF, granulocyte-macrophage colony-stimulating factor; IP, interferon gamma-induced protein; IL, interleukin; IL1-ra, IL-1 receptor antagonist; sgp, soluble glycoprotein; sIL-6R, soluble IL-6 receptor, TNF, tumor necrosis factor.